Associations
These links are provided for your convenience. However, they lead to external websites not created, managed, or maintained by Baxter. Baxter is not responsible for, and does not necessarily endorse, the opinions or products represented on these external pages.
Professional Links
American Academy of Allergy, Asthma & Immunology
611 East Wells Street
Milwaukee, WI 53202
414-272-6071
www.aaaai.org
American College of Chest Physicians
3300 Dundee Road
Northbrook, IL 60062-2348
847-498-1400
www.chestnet.org
www.chestjournal.org
American Association for Respiratory Care
9425 N. MacArthur Blvd. Suite 100
Irving, TX 75063-4706
www.aarc.org
American Thoracic Society
61 Broadway
New York, NY 10006-2747
212-315-6440
www.thoracic.org
Global Initiative for Chronic Obstructive Lung Disease
Journal for Respiratory Care Practitioners
Education Links
Alpha-1 Advocacy Alliance
P.O. Box 202, 103 Rapidan Church Lane
Wolftown, VA 22748
1-866-FOR-A1AA or 1-866-367-2122
www.alpha1advocacy.org
The National Organization for Rare Disorders
55 Kenosia Avenue, P.O. Box 1968
Danbury, CT 06813-1968
203-744-0100
www.rarediseases.org
Alpha-1 Association
1225 Eye Street NW, Suite 1225
Washington, DC 20005-5918
800-521-3025
www.alpha1.org
Alpha-1 Foundation
2937 SW 27th Avenue, Suite 302
Miami, FL 33133
1-877-2-CURE-A1
www.alphaone.org
American Lung Association
National Library of Medicine
National Heart, Lung, and Blood Institute
Pulmonary Education & Research Foundation
Everything Respiratory Magazine
ARALAST NP [Alpha1-Proteinase Inhibitor (Human)]
ARALAST NP is indicated for chronic augmentation therapy in patients having congenital deficiency of A1-PI with clinically evident emphysema. ARALAST NP is not indicated as therapy for lung disease patients in whom congenital A1-PI deficiency has not been established.
The effect of augmentation therapy with ARALAST NP on pulmonary exacerbations and on the progression of emphysema in alpha1-antitrypsin deficiency has not been demonstrated in randomized, controlled clinical trials.
Please review the Important Risk Information and the Full Prescribing Information
Please review the Important Risk Information and the Full Prescribing Information
